Aminoglycosides are antibacterial therapeutic agents that contain amino-modified glucose. They can kill bacteria like staphylococci and few mycobacteria. They also serve as a second line of defense against basic infections immune to basic antibacterials. Rising tuberculosis incidences in low-income countries will spur the demand for these agents.
Health initiatives like UNITAID and Global Drug Facility (GDF) that manage alarming tuberculosis cases would influence the aminoglycoside market. Side effects (like muscle twitching and seizures) associated with this product can hinder the market.
Full research report on Global Aminoglycosides Market Analysis:
The market was valued over USD 1.1 billion in 2014. It is projected to reach around USD 1.7 billion by 2022, at 3.5% CAGR during the forecast period (2015 to 2022). Disapproval of aminoglycoside medicines in certain regions should result in subordinate growth.
Streptomycin, kanamycin, neomycin, gentamicin, amikacin, and tobramycin are the products in the aminoglycoside market. Neomycin and tobramycin together constituted over USD 600 million. These drugs can treat major bacterial infections. Neomycin treats varied skin infections. Tobramycin is effective against Pseudomonas aeruginosa infections.
By administration routes, the market is divided into oral, feed, topical, intra-mammary, and injectables (parenteral). Among these, injectables accounted for the largest revenue. They treat tuberculosis, MDR-TB (multi-drug-resistant tuberculosis), and XDR-TB (extensively drug-resistant tuberculosis).
Request for sample of this research report:
On the basis of applications, the aminoglycoside market is segmented into veterinary, skin infections, UTI (urinary tract infections) & pelvic diseases, and respiratory diseases. Respiratory diseases were the largest application in 2014. Veterinary treatment will experience limited growth over the forecast period on account of animal diseases.
In view of regions, Asia Pacific accounted for the largest share in 2014. This was attributed to alarming MDR-TB cases in the region. South Africa led the MEA (Middle East & Africa) market due to high regional demand for injectables. Unavailability of aminoglycosides in the United States will lead to decreased regional incomes.
Antibiotic resistance variations in different countries account for varied patterns, volumes, and revenues. Key players of the worldwide aminoglycoside market comprise Medson Pharmaceuticals, Vega Pharma Ltd., HuvePharma, and Kremoint Pharma Pvt. Ltd. Owing to shortage in the suppliers & manufacturers of some aminoglycoside medicines, new players are estimated to participate. However, absence of regulatory sanction could hinder their participation.
View more reports of this category by Grand View Research at:
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.
For more information, visit: http://www.grandviewresearch.com/
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States